Cancer discovery
Two Drugs, One Stunning Myeloma Result.
Published: 202510.1158/2159-8290.CD-NW2025-0114
Abstract
By pairing a BCMA-targeted T-cell engager with an anti-CD38 antibody, researchers achieved strikingly deep remissions and sharply reduced relapse risk in patients with relapsed myeloma. The results suggest this dual immune-directed strategy could cha…
Preview only. Read the full abstract at the source